(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 14.68% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 2.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 126.66%.
Exagen's revenue in 2025 is $58,862,000.On average, 3 Wall Street analysts forecast XGN's revenue for 2025 to be $1,485,245,768, with the lowest XGN revenue forecast at $1,474,243,947, and the highest XGN revenue forecast at $1,507,249,409.
In 2026, XGN is forecast to generate $1,698,681,085 in revenue, with the lowest revenue forecast at $1,694,280,357 and the highest revenue forecast at $1,707,482,542.